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 A large body of evidence demonstrates positive, graded effects of PA on cardiovascular disease 
(CVD) morbidity and mortality with increasing intensity compared with lower PA intensity. Running 
is often designated as a high-intensity PA with substantial evidence supporting its health benefits. 
Cross-country skiing is among the most demanding aerobic endurance exercises and requires engaging 
the upper- and lower-body. Cross-country skiing is often regarded as high-intensity PA, which has 
been associated with significant health benefits. However, a robust body of evidence identifying the 
dose-response relation between cross-country skiing volume and health outcomes is sparse. Therefore, 
this review aims to summarize the available evidence linking cross-country skiing with CVD 
morbidity and all-cause mortality; postulated pathways that may elucidate the relation between these 
associations; outline areas of ongoing uncertainty; and the implications for primary and secondary 
CVD prevention. To put the findings into perspective, we also summarized the evidence linking 
running with CVD morbidity and all-cause mortality. Though a head-to-head comparison is not 
available, the evidence indicates that performing PA as cross-country skiing associates with lower 
mortality risk when compared with that observed in those undertaking their PA as running. Potential 
adverse effects of extreme high weekly doses of cross-country skiing over decades may be cardiac 
arrhythmias, such as atrial fibrillation. Evidence suggests that cross-country skiing may reduce the risk 
of CVD events and all-cause mortality via anti-inflammatory pathways, improvements in endothelial 
function and reduced levels of CVD risk factors, such as lipids, glucose, and blood pressure; and 
enhancement of cardiorespiratory fitness. 
 

















HIPA-High intensity physical activity 
MI-Myocardial infarction 
MIPA-Moderate intensity physical activity 
PA-Physical activity 






The positive association between physical activity (PA) and/or exercise training with disease 
prevention is well established. 1, 2 Numerous epidemiologic and randomized controlled trials have 
contributed to identifying the volume of PA necessary to accumulate substantial health benefits across 
populations. Over the course of this work, many iterations of PA guidelines have led to the most recent 
recommendations of accumulating 150-300 min/week of moderate-intensity or 75-150 min/week of 
vigorous-intensity aerobic PA/exercise for adults, or a combination of the two in addition to 
completing at least two days of strength training.1  The most common moderate- and vigorous-
intensity aerobic PAs are listed in Table 1.  These PA guidelines are purposefully broad in order to 
apply to most all individuals, however, there currently exists much interest in identifying ways to 
optimize health related outcomes that extend beyond what is generally experienced by performing the 
current recommendations. Many studies have presented compelling evidence suggesting vigorous or 
high-intensity PA (HIPA) is associated with significantly greater improvements in cardiorespiratory 
fitness (CRF) (well established for its beneficial effects on cardiovascular (CV) disease (CVD) 
outcomes and mortality3, 4), oxidative capacity of the skeletal muscle, vascular function, larger 
reductions in risk of chronic diseases, including hypertension, diabetes, CVD, as well as all-cause 
mortality, compared with lower or moderate intensity PA (MIPA). 5-11   
Several studies have examined the associations of participating in leisure- time moderate and high-
intensity activities with CVD risk factors, risk of major chronic disease outcomes as well as all-cause 
mortality.5-9, 12, 13,14 In a recent study consisting of 80,306 British adults, individuals taking part in sport 
or exercise activities were found to have significant reductions in all-cause mortality compared to 
those that did not.15 All-cause mortality was significantly reduced in cyclists (hazard ratio (HR) 0.85, 
95% confidence interval (CI) 0.76 to 0.95), swimmers (HR 0.72, 95% CI 0.65 to 0.80), racquet sports 
(HR 0.53, 95% CI 0.40 to 0.69) and aerobics (HR 0.73, 95% CI 0.63 to 0.83). However, only those 
that took part in swimming, racquet sports and aerobics experienced significant reduction in CVD 




include more HIPA, may have significant benefits for public health and recommended that future 
studies should aim at strengthening the epidemiological evidence based on sports and health. 
 
Cross-country skiing, in particular, is categorized as a HIPA that is undertaken as a leisure time PA or 
long-term endurance sport and is enjoyed by the general public as well as by athletes in competitive 
settings. While there are studies that have identified health benefits experienced with cross-country 
skiing, data on the association of cross-country skiing with CVD and all-cause mortality outcomes are 
relatively sparse compared to investigations on the effects of walking and running. The main purpose 
of this review is to 1) summarize the available epidemiological and interventional evidence linking 
cross-country skiing with CVD outcomes and all-cause mortality, 2) explore mechanisms underlying 
possible associations, 3) outline areas that require further investigation and 4) the implications for 
primary and secondary prevention. To accomplish this, we sought observational (prospective cohort, 
nested case-control, or case-control, retrospective cohort) studies, randomized controlled trials (RCTs), 
and non-RCTs from MEDLINE and EMBASE from their inception until December 2018. The 
computer-based searches combined free and Medical Subject Headings search terms and combination 
of key words related to the intervention (“skiing”, “skiers”) and outcomes (“cardiovascular disease”, 
“death”, “mortality”). Studies were limited to those conducted in humans, adults and written in 
English. Several reports have addressed the potential benefits of running, a very popular HIPA;16-20 
however, to put the findings into perspective, we also briefly summarized the existing evidence on 
running and its impact on CVD, as well as CVD- and all-cause mortality. 
 
Existing Evidence on Cross-Country Skiing, CVD Morbidity and Mortality 
Although interest in the relation between various sporting activities and adverse outcomes dates back 
several decades, the relation between cross-country skiing and mortality was first published in 1974 by 
Karvonen et al. In their study, 396 elite cross-country skiers were identified from records of annual 




and 1910 and were followed up until 1967 and were found to live 4 years longer than the national 
average life span.21 Consequently, this study spurred numerous investigations that aimed to examine 
the relation of cross-country skiing with CVD and mortality outcomes (Table 2). In 1993, Sarna and 
colleagues published an assessment of the life expectancy and mortality of 2613 Finnish male world 
class athletes who competed in cross-country skiing, track and field athletics, soccer, ice hockey, 
basketball, boxing, wrestling, weight lifting, or shooting.22 This group was compared to a cohort of 
healthy men selected from the Finnish Defense Forces. When stratified by sport, those in the 
endurance category (cross-country skiing and long distance running) had the lowest mortality odds 
ratio [0.49, 95% CI 0.26 to 0.93] and the highest life expectancy odds ratio (75.6, 95% CI 73.6 to 77.5 
years) compared to athletes in team or power sports and the healthy controls. Furthermore, the authors 
concluded that these observations were mainly due to decreased CVD mortality in those that 
participated in endurance sports. Grimsmo and colleagues compared CVD morbidity and mortality 
outcomes among long-term endurance cross-country skiers with that of the general population.23 This 
cohort of cross-country skiers were followed for 30 years and the findings showed that these male 
athletes lived longer than males in the general population, where CVD was the major cause of deaths. 
In addition to prolonging life, prior participation in cross-country skiing has been demonstrated to 
reduce risk of recurrent CVD events and recovery time. The largest cohort study of 708,614 
participants (Vasaloppet skiing study) matched cross-country skiers with a history of a stroke to non-
skiers with a comparable history of stroke. Skiers were found to have a 30% relative risk reduction of 
all-cause death [adjusted HR, 0.70 (95% CI 0.56 to 0.87)], with no significant risk difference for 
recurrent stroke events compared with non-skiers [adjusted HR, 1.02 (95% CI 0.84 to 1.24)].24 
Furthermore, it appeared as though regularly participating in cross-country skiing attenuated post 
stroke functional declines as skiers maintained greater performance of activities of daily living, were 
less dependent, rated their health higher, were less depressed and used fewer medications compared 
with their non-skier counterparts who had a previous history of stroke. Hallmarker and colleagues 




infarction (MI) with non-skiers and observed that skiers had a 20% lower subsequent risk of recurrent 
MI or death [adjusted HR, 0.80 (95% CI 0.67 to 0.97)].25 Though these studies clearly demonstrated 
the protective effects of being a cross-country skier, they are significantly limited by the lack of data 
characterizing the volume of skiing performed by individuals. Therefore, our group recently quantified 
the volume of leisure time cross-country skiing performed by 2087 middle-aged men,26 and examined 
its association with all-cause mortality over a median observation period of 26 years using the well-
established Kuopio Ischemic Heart Disease (KIHD) prospective cohort study. Compared to men who 
did not participate in cross-country skiing, any volume of cross-country skiing was associated with 
significant reductions in all-cause mortality (1-200 MET hours per year, HR 0.84 95% CI, 0.73 to 
0.97; >200 MET hours per year, HR 0.80, 95% CI 0.67 to 0.96). These findings were similar when 
separating participation by hours of skiing performed per week (1-60 min/wk, HR 0.84, 95% CI 0.72 
to 0.97; >60 min/wk, HR 0.82, 95% CI 0.69 to 0.97) and independent of several potential confounders 
including total PA.25 Cumulative hazard curves demonstrated a greater risk of all-cause mortality 
among participants who did not do any cross-country skiing (n=821) compared to the other groups 
(n=1266) (Figure 1).26 A dose-response analysis suggested a continuous association between total 
volume of leisure-time cross-country skiing and the risk of all-cause mortality, consistent with a 
curvilinear or linear shape with no apparent threshold effect (Figure 2). Based on the KIHD cohort, we 
have recently shown that compared to men who did not participate in cross-country skiing, a volume 
of > 200 MET hours per year of cross-country skiing was associated with significant reduction in acute 
MI, multivariable adjusted HR 0.81, 95% CI 0.66 to 0.98).27 In an investigation of all-cause mortality 
outcomes and health-related behavior among former Finnish male elite athletes who participated in 
various sports including cross-country skiing (n=900) and their age-matched brothers (n=900), the 
former athletes were observed to live 2-3 years longer than their brothers [age-adjusted hazard ratio for 
endurance sports, 0.61 (95% CI 0.45 to 0.82)].28In line with our demonstration of a dose-response 
relation, Hallmarker et al.  studied 399,630 Swedish individuals in which half the sample were long-




had reduced risk for all-cause mortality [adjusted HR, 0.52 (95% CI 0.49 to 0.54)], MI [adjusted HR, 
0.56 (95% CI 0.52 to 0.60)], and stroke [adjusted HR, 0.63 (95% CI 0.58 to 0.67)] and for all the three 
outcomes combined [adjusted HR, 0.56 (95% CI 0.54 to 0.58)] compared with the general 
population.29 Notably, however, a higher risk of death, MI and stroke was seen in long-distance skiers 
with slower racing times [age-adjusted HR per doubling of race time, 1.19 (95% CI 1.07 to 1.32)]. We 
have recently shown that total volume and duration of leisure time cross-country skiing are each 




Implicated Pathways Underlying Associations Between Cross-Country Skiing and Outcomes 
A defining characteristic of cross-country skiing is the simultaneous use of the upper and lower body, 
while simultaneously working both the “pulling” and “pushing” muscles of a lower and upper body. 
The engagement of a larger muscle mass compared to common activities such as walking, running and 
cycling, increases exercise intensity and places a greater demand on the CV and metabolic systems. As 
a result, highly trained elite cross-country skiers have been shown to have similar relative 
mitochondrial volume as well as the number of capillaries per fiber area are the same in the arms and 
legs.31  
 
There are multiple pathways by which cross-country skiing may decrease the risk of chronic diseases, 
such as CVD and mortality. Given the graded association between higher levels of PA with health 
benefits, cross-country skiing may reduce the risk of CVD and other outcomes as it is considered a 
HIPA.  This likely occurs through physiological and metabolic adaptations, such as (i) improvements 
in endothelial function, decreased body weight, blood pressure, natriuretic peptides, lipid profiles, 
improvements in glucose tolerance, hemostatic factors, and cardiac troponin T;12, 32-34 (ii) anti-




skiing may increase neuromuscular function, left ventricular function and blood volume; stimulate 
angiogenesis; and increase vasodilation and hormonal effects, that may positively modulate oxygen 
uptake and CRF.29 Also, cross-country skiing via its effect on obesity, may also reduce mortality 
through decreasing cancer risk.39  
 
Compared to non-skiers, cross-country skiers have a better cardiometabolic risk profile. In the study of 
Vasaloppet skiers,29 smoking, diabetes and hypertension, which are important risk factors for 
atherosclerotic CVD events, were significantly less frequent among the cross-country skiers when 
compared to non-skiers. In comparing CVD morbidity and mortality outcomes among long-term 
endurance cross-country skiers with that of the general population, Grimsmo and colleagues also 
observed that cross-country skiers had a favorable CVD risk profile (low blood pressure, favorable 
lipid levels, low prevalence of diabetes and obesity) compared with the general population.23 In a case-
control study that compared the lipid profile of healthy male sedentary controls with professional 
endurance athletes who included professional male cross-country skiers, adverse lipid abnormalities 
were mostly absent in the skiers compared to the control group.40  
 
Since cross-country skiing is usually only possible during the winter months, its beneficial effects on 
adverse health outcomes and mortality is suggested to reflect individuals’ seasonal PA habits and the 
ability to perform HIPA.28, 29  Individuals who participate in long-distance ski racing have a high level 
of PA during the winter months, but are also likely to maintain regular PA throughout the year by 
walking, cycling and running. Though there is a possibility that the beneficial effects of cross-country 
skiing may reflect total endurance PA, our recent study on leisure-time cross-country skiing and all-
cause mortality suggested otherwise.26 Our findings showed that the association was independent of 
total PA, thus suggesting that the amount of skiing may have direct effects on adverse outcomes. 
However, some earlier studies23,26 did not take into account the effects of other types of PA on the 




examine the independent health benefits of cross-country skiing accounting for other types of PA.  
 
The majority of cross-country skiers undergo intense training (HIPA) for at least four hours per week, 
which is on average much more than the general population. Regarding CRF levels in cross-country 
skiers, the maximum oxygen uptake (VO2max) is between 45 and 85 mL∙kg
-1∙min-1, 41-45 compared with 
the general population level of about 35 mL∙kg-1∙min-1.  VO2max is strongly correlated with endurance 
performance. Female cross-country skiers have reported average VO2max values of up to 70 mL∙kg
-
1∙min-1,42-45 whereas males have reported average values of up to 85 mL∙kg-1∙min-1.43-45  In fact, elite 
cross-country skiers have the highest recorded VO2max levels of any group of athletes; ∼80 
mL·kg−1·min−1 in female and  ∼90 mL·kg−1·min−1 in male cross-count skiers can be described as 
upper human limits in aerobic power.45-47 Cross-country skiing involves the use of the large muscle 
groups of both the upper and lower body; therefore, during this HIPA, there is a large demand for 
oxygen to be supplied to these muscles. There is evidence to suggest that genetic differences may 
explain the differences in mortality risk between cross-country skiers and their non-skiing 
counterparts.28 There is a possibility that genetic factors may explain different responses to regular 
exercise e.g. oxygen uptake or influence on risk factors.48 An interesting question that remains to be 
answered is if high-level endurance athletes may have different physiologic responses to exercise and 
therefore lower risk for CVD.44,49 
 
Potential Adverse Effects of Cross-Country Skiing 
There have been previous suggestions that the HIPA might be harmful, particularly for athletes who 
engage in marathons and cycling races. The intensities and volumes of these HIPA regimens far 
exceed those proposed by guideline recommendations.1  Indeed, biochemical as well as 
echocardiographic evidence of minor cardiac injury have been observed in high level endurance 
runners and athletes after long distance competitions.50-52 Similar to these previous findings, there have 




deaths during long-distance skiing races.53, 54 Available data also suggests that atrial fibrillation (AF), 
which is one of the most common cardiac arrhythmias, can also occur in high endurance athletes like 
cross-country skiers; though the evidence has been inconsistent. Among male participants of a long 
distance Swedish cross-country skiing event, a faster finishing time and a high number of completed 
races were associated with higher risk of arrhythmias, including AF.53 In the largest study conducted 
among cross-country skiers and non-skiers with previous history of stroke, though cross-country skiers 
had a reduced risk of mortality, they had a higher incidence of AF.24 In a retrospective cohort study 
that compared cross-country male skiers with males from the general population, years of regular 
endurance exercise was found to be associated with increased risk of AF and atrial flutter.55 
Accordingly, long-term endurance cross-country skiers have a greater prevalence of AF compared to 
the general population.56, 57 The majority of cross-country skiers still engage in PA or exercise after the 
onset of AF, as there is a potential for exercise to reduce symptoms of AF and death among veteran 
endurance athletes with AF.56 Physically active people will only spend a small amount of their life 
time in these competitive races, hence the short-term excess risk of adverse events during these periods 
is by far outweighed by the long-term protective effects of cross-country skiing on mortality.54 The 
high level of PA in a cohort of cross-country skiers with a history of MI protected them substantially 
against recurrent MI or death compared to their counterparts who were non-skiers.25 Some other 
studies have however not demonstrated differences in the risk of AF between cross-country skiers and 
non-skiers.29 Although there might be some adverse effects such as AF associated with high doses of 
cross-country skiing, there is limited data elucidating the volume of cross-country skiing beyond which 
does not provide additional overall health benefits (Figure 2).26 Although the Vasaloppet cross-
country skiers or those individuals who exercise for 20-30 hours per week have increased risk for AF, 
these same individuals have increased longevity. More importantly, the increased incidence of AF is 
not caused by too much PA in the general population, but rather too little PA in combination with an 
unhealthy lifestyle. Nevertheless, additional studies on the dose-response relationships between cross-





There may be an increased short-term risk of sudden coronary events during HIPA, especially in cold 
temperatures – a typical scenario for cross-country skiing. When emphasizing the importance of high 
CRF and increased PA, it is important to emphasize that exercise-related risks should also be 
considered as there may be more fatal adverse events among previously sedentary middle-aged and 
older individuals who start HIPA (without any appropriate health screening tests) than among those 
who have been active for long periods. Some of these acute CVD events may be due to atherosclerotic 
plaque rupture during exertion, which is one of the most unpredictable mechanistic pathways leading 
to sudden death during or after demanding HIPA/ exercise. Muscular skeletal injury rates are also  
very low in cross-country skiing compared to slalom or downhill skiing and are mostly chronic in 
nature.58 Chronic anterior compartment syndrome  is a potential cause of chronic pain in cross-country 
skiers.59 and develops in cross-country athletes who practice daily at high intensity as a result of 
overuse injury of the muscles or muscle imbalance. Other very rare adverse effects reported are back 
pain, injuries and deaths associated with trauma and accidents.60, 61  
 
 
Running and CVD and Mortality 
The major emphasis of this review is cross-country skiing, as opposed to running, since many of the 
papers have addressed the potential benefits of running.16-20 However, running is a very important 
HIPA that is available to many across the world and is possible in most seasons and climates. Running 
is associated with marked benefits in CVD and all-cause mortality. 
 
Certainly, all types of PA are associated with benefits, but as reviewed above, HIPA is probably 
associated with more marked benefits, such as with many leisure time sporting activities and, 
especially, running.16-20, 62-68 Several years ago, we  reviewed the effects of running on chronic diseases 





Although, there are numerous  studies on running and CVD in the literature, we especially reviewed 
the data from the National Runner's and Walker's Health Study, the Running Aging Study, the 
Copenhagen City Heart Study,18, 66 and especially the Aerobics Center Longitudinal Study (ACLS),19, 
67 which are all reviewed in detail elsewhere.16, 17 However, in this report, we will mostly emphasize 
the data from the ACLS, which is perhaps the largest and most robust from a CVD - and all-cause 
mortality standpoint, including emphasis on dose-response relationship of running and mortality.16, 17, 
19, 67, 68 
 
Running - ACLS Data 
In the ACLS, 55,000 individuals (13,000 runners) were followed for nearly 15 years to assess the 
impact on CVD - and all-cause mortality compared with nonrunners.  In this large study, the runners 
had reductions in CVD - and all-cause mortality of 30% and 45% (Figure 3), respectively, accounting 
for an estimated increase in average survival of 3.0 and 4.1 years for all-cause and CVD - related 
survival, respectively, after adjusting for lifestyle factors and medical conditions.67 Persistent runners 
appear to receive the full benefit from running for mortality reductions, whereas those who were 
nonrunners but who started running during the study and those who started running  but later stopped 
appeared to receive nearly half of the benefit received from CVD - and all-cause mortality reductions. 
Although, these results are impressive, many would not find this to be particularly surprising, since 
running may be expected to produce improvements in health, and those who were able to run may 
represent selection bias in favor of the runners. 
 
However, when assessing the relative doses of running, somewhat surprising results emerged. Runners 
generally had considerably higher levels of CRF than did nonrunners, and the levels of CRF in the 
runners generally progressively increased with increasing running doses (Figure 4).67    Most evidence 




suggest progressively better survival as CRF progressively increases.16, 17, 20, 62, 64, 69 However, when 
the 13,000 runners were divided into quintiles (Q) of running doses, such as miles per week, times per 
week, minutes per week, etc., no statistically significant differences were noted for CVD – and  all-
cause mortality between the five running groups (Figure 5), although the trend appeared to be more 
favorable in those with faster running times.67 In fact, those who were in Q1 for the various dosages 
categories (e.g. < 6 miles per week, running only 1-2 times per week, < 51 minutes per week, and > 6 
mph running pace) received the full benefit from running with respect to reductions in CVD - and all-
cause mortality (Figure 4).67 These results suggested that maximal benefits of this HIPA occur at quite 
modest running/ jogging doses and that runners in Q1 have almost similar benefit as did those Q2-4 
and had a slight non-statistically significant trend of greater benefit than those who are the Q5 runners. 
 
In contrast to the results of the Copenhagen City Heart Study,18, 66 which would suggest the loss of 
benefit or even potentially harm of moderate-doses of running, our results from a larger sample with 
much better statistical power indicated that runners with Q5 still had significantly better CVD - and 
all-cause survival compared with nonrunners.16, 17, 67, 68 However, the higher doses of running were not 
necessary to achieve maximal CVD - and all-cause mortality reductions.  Also, when we later divided 
the Q5 runners further into tertiles (T1-3), we found that the highest tertile (Q5,T3), or the top 7% of 
running doses, actually appear to lose the benefit, compared to the nonrunners, although there was no 
increase in mortality risk, suggesting “more was still not bad” (Figure 6).19 However, when compared 
to the low dose of running (Q1) in MET-min/week (not compared to the nonrunners), which generally 
provides the most favorable mortality benefits, the relative risk of CVD mortality (HR 1.66, 95% CI 
0.87 to 3.16) and all-cause mortality (HR 1.27, 95% CI 0.89 to 1.81) were higher in the highest 
running group (T3) although still not significant, which  raised concerns that "more could be worse." 
 
Additional Benefits of Running 




running, improvements in weight and reductions in obesity indices, hypertension, dyslipidemia, type 2 
diabetes, osteoarthritis, need for hip replacement, benign prostatic hypertrophy, disability, respiratory 
diseases, cancers, and stroke have also been reported with running, and are reviewed in detail 
elsewhere.16, 17 
 
Potential Adverse Effects of Very High Running Doses 
Besides the potential toxicity discussed elsewhere, and which was discussed with high doses of skiing, 
running extreme distances can also have potential toxicity (Figure 7),70 including cardiac dilation and 
dysfunction and the release of troponin, brain natriuretic peptides and cardiac arrhythmias, especially 
AF.20, 70, 71 At present, we agree with Levine regarding the overall safety of high intensity and high 
volume exercise70-72 and that this evidence is not currently strong enough to try and persuade heavy 
endurance exercises to avoid these activities.20, 72  Nevertheless, from a public health standpoint, it is 
best to emphasize that the maximal benefit of HIPA, such as running, occur at low to modest levels.  
Higher doses of running, however, may be required for competition (eg. to improve running times) or 




Overall, the evidence on the potential beneficial effects of cross-country skiing on CVD morbidity and 
mortality are based on observational study designs, which are limited by potential biases such as 
reverse causation, residual confounding, and/or regression dilution bias. The majority of studies did 
not adjust for other types of PA. Therefore, further studies are warranted to examine the independent 
health benefits of cross-country skiing accounting for other types of activities. Though head-to-head 
comparisons are not available, the evidence based on reported risk estimates suggest that cross-country 
skiing may be associated with substantial mortality benefits compared with running. Although some 
studies suggested that there may be potential adverse effects such as AF associated with high doses of 




beyond which more cross-country skiing does not provide further benefits or is possibly harmful. 
Nevertheless, evidence on the cardiovascular and mortality benefits seems to far outweigh the risks. So 
far evidence from our study suggests a continuous dose-response relationship between total volume of 
cross-country skiing and all-cause mortality;26 a finding which may be consistent with that of PA and 
outcomes, such as CVD and mortality.11 However, more comprehensive studies on the dose-response 
relationships between cross-country skiing and various health outcomes are warranted. 
 
It is reported that during winter, PA can decrease by up to 40%.71 This subsequently results in adverse 
cardiometabolic risk profiles, such as increase in blood pressure, weight, and harmful cholesterol, 
which are precursors for coronary and other CVD mortality. There is substantial evidence that the 
prevalence of physical inactivity and sedentary behavior is high globally.73 Temporal changes in PA 
level, including HIPA, can be tracked to promote improvements in CRF which is a key element in 
CVD risk reduction.4, 74-76 Therefore, PA/exercise or sports that are attractive to and feasible for the 
wider population, such as running, need to be identified to promote PA/exercise and health during the 
winter. Cross-country skiing, as well as running and hiking, is a potential PA that can be taken up by 
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Table 1. Examples of moderate- and vigorous-intensity aerobic physical activities 
 
Moderate-intensity physical activity Vigorous-intensity physical activity  
Brisk walking  Jogging (> 10 minutes/mile) 
Bicycling (< 10 miles/hour) Running (≤ 10 minutes/mile) 
General gardening Bicycling (≥10 miles/hour) 
Ballroom dancing Swimming laps 
Water aerobics Tennis (singles) 
Tennis (doubles) Squash or racquetball 
 Rowing 





Table 2. Key prospective studies that have assessed the associations of cross-country skiing with 
cardiovascular disease and mortality outcomes 
 






















       












Life expectancy of general 
male population was 2.8 
years less than the skiers 
 
Sarna, 1993 Cross-country 
skiing athletes 





Increased life expectancies 
and decreased CVD 
mortality in skiers 
Grimsmo, 2011 Long-term 
endurance 
122 CVD (21) 
Mortality (37) 




Reduced CVD morbidity 
and mortality compared 
with general population 
Hallmarker, 2015 Long-term 
endurance 








HR (95% CI) for recurrent 
stroke 0.96 (0.79-1.17) 
and mortality 0.70 (0.56-
0.87) 
Hallmarker, 2016 Long-term 
endurance 
703,581 1,515 Skiers with first-
time MI (n=1039) 
vs non-skiers with 
first-time MI 
(n=6053) 
Recurrent MI and 
mortality 
HR (95% CI) for recurrent 
MI mortality 0.80 (0.67-
0.97) 
Laukkanen, 2018 Leisure-time 2,087 1,028 Volume and 
duration of skiing 




HR (95% CI) for > 200 
MET hrs per year 0.80 
(0.67-0.96) 
and > 60 mins per week 
0.82 (0.69-0.97) 
Kontro, 2017 Cross-country 
skiing athletes 





HR (95% CI) for all-cause 
mortality in all athletes 0.75 
(0.65-0.88) and for the 
endurance group 0.61 
(0.45-0.82) 






Skiers vs non-skiers  Mortality, MI, or 
stroke 
HR (95% CI) for mortality 
0.52 (0.49-0.54), MI 0.56 
(0.52-0.60), stroke 0.63 
(0.58-0.67), and all 
outcomes 0.56 (0.54-0.58) 
Laukkanen, 2019 Leisure-time 2,589 808 Volume and 
duration of skiing 
for skiers vs non-
skiers 
Acute MI HR (95% CI) for > 200 
MET hrs per year 0.81 
(0.66-0.98) 
and > 60 mins per week 
0.84 (0.69-1.02) 








Figure 1. Cumulative Kaplan-Meier curves for all-cause mortality during follow-up according to total 
volume and duration of cross-country skiing.  Reproduced with permission from Scand J Med Sci 
Sports. 2018 Laukkanen et al25 
 
Figure 2. Restricted cubic splines of the hazard ratios of all-cause mortality with total volume (METs 
per year) of cross-country skiing.  Models were adjusted for age, body mass index, systolic blood 
pressure, high-density lipoprotein cholesterol, smoking status, alcohol consumption, prevalent 
coronary heart disease, history of diabetes mellitus, resting heart rate, and physical activity. Data 
adapted from Scand J Med Sci Sports. 2018 Laukkanen et al25 
 
Figure 3. The reference group for all analyses includes nonrunners. All hazard ratios (HRs) were 
adjusted for baseline age (years), sex (not in sex-stratified analyses), examination year, smoking status 
(never, former, or current [not in smoking-stratified analyses]), alcohol consumption (heavy drinker or 
not [not in alcohol drinking-stratified analyses]), other physical activities except running (0, 1 to 499, 
or ≥500 MET-min/week), and parental cardiovascular disease (yes or no). Unhealthy was defined as 
the presence of 1 or more of the following health conditions: abnormal electrocardiogram (ECG), 
hypertension, diabetes, or hypercholesterolemia. Heavy alcohol drinking was defined as >14 and >7 
drinks per week for men and women, respectively. BMI = body mass index.  Reproduced from J Am 
Coll Cardiol 2014 Lee DC, et al.67 
 
Figure 4. Cardiorespiratory fitness was estimated from the final treadmill speed and grade during the 
maximal exercise test in a subsample of 50,995 participants. All p values for linear trend across weekly 
running time were <0.001 after adjustment for age and sex (not in sex-stratified analyses).  J Am Coll 





Figure 5. Hazard ratios (HRs) of all-cause and cardiovascular mortality by running characteristic 
(weekly running time, distance, frequency, total amount, and speed).  Participants were classified into 
6 groups: nonrunners (reference group) and 5 quintiles of each running characteristic. All HRs were 
adjusted for baseline age (years), sex, examination year, smoking status (never, former, or current), 
alcohol consumption (heavy drinker or not), other physical activities except running (0, 1 to 499, or 
≥500 MET-minutes/week), and parental history of cardiovascular disease (yes or no). All p values for 
HRs across running characteristics were <0.05 for all-cause and cardiovascular mortality except for 
running frequency of ≥6 times/week (p = 0.11) and speed of <6.0 miles/h (p = 0.10) for cardiovascular 
mortality.  J Am Coll Cardiol 2014 Lee DC, et al.67 
 
Figure 6. Hazard ratios of all-cause and cardiovascular disease (CVD) mortality by weekly running 
time, distance, frequency, and total amount.  Participants were classified into 8 groups: nonrunners and 
5 quintiles of each running dose (Q1 to Q5) with the last quintile (Q5) additionally categorized into 3 
tertiles (Q5-T1, Q5-T2, and Q5-T3) using larger markers (7 groups for running frequency because of 
limited numbers in ≥ 7 times/wk). All hazard ratios were adjusted for baseline age (years), sex, 
examination year, smoking status (never, former, or current), alcohol consumption (heavy drinker or 
not), other physical activities except running (0, 1-499, or ≥500 metabolic equivalent task minutes per 
week [MET-min/wk]), and parental CVD (yes or no). The number of participants (number of all-cause 
deaths) were 42,121 (2857), 2710 (110), 2584 (116), 2505 (103), 2647 (112), 850 (33), 822 (30), and 
898 (52) in the corresponding 8 running time groups from nonrunners to Q5-T3; 42,121 (2857), 2626 
(105), 2473 (120), 2961 (123), 2218 (92), 885 (36), 1027 (40), and 826 (40) in running distance; 
42,121 (2857), 2757 (62), 3076 (105), 2817 (131), 2500 (143), 1215 (66), and 651 (49) in running 
frequency; and 42,121 (2857), 2609 (109), 2598 (122), 2558 (116), 2626 (105), 863 (31), 886 (30), and 
876 (43) in total running amount. The number of participants (number of CVD deaths) were 40,319 




corresponding 8 running time groups from nonrunners to Q5-T3; 40,319 (1055), 2550 (29), 2386 (33), 
2874 (36), 2156 (30), 858 (9), 1001 (14), and 797 (11) in running distance; 40,319 (1055), 2714 (19), 
2993 (22), 2725 (39), 2396 (39), 1174 (25), and 620 (18) in running frequency; and 40,319 (1055), 
2531 (31), 2508 (32), 2477 (35), 2553 (32), 842 (10), 864 (8), and 847 (14) in total running amount. 
The bars indicate 95% CIs, and hazard ratios appear next to the bars.  Reproduced with permission 
from Mayo Clin Proc 2016 Lee DC et al.19 
 
Figure 7. Proposed pathogenesis of cardiomyopathy in endurance athletes. BNP = B-type natriuretic 
peptide; CK-MB = creatine kinase MB; LV = left ventricle; RA = right atrium; RV = right ventricle; 
SCD = sudden cardiac death.  Reproduced with permission from Mayo Clin Proc 2012.  Reproduced 
with permission from Mayo Clin Proc O’Keefe JH et al.70 
 
 
